Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* .Diagnosis of type 2 diabetes mellitus prior to informed consent~* Male and female patients, on diet and exercise regimen, who are pre-treated with one of the following oral antidiabetic drugs: sulfonylurea, glinide, biguanide, Alpha-glucosidase inhibitor (a-GI), dipeptidyl peptidase-IV (DPP-IV) inhibitor or thiazolidinedione~* glycosylated haemoglobin (HbA1c) at Visit 1: \>=7.0 to =\<10.0% (national glycohemoglobin standardization program)~Exclusion criteria:~* Uncontrolled hyperglycaemia with a glucose level \>240 mg/dL (\>13.3 mmol/L)~* Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent~* Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): BI 10773 low dose tablet once daily
- BI 10773 high dose (Type: EXPERIMENTAL): BI 10773 high dose tablet once daily
- Metformin (Type: ACTIVE_COMPARATOR): Metformin tablets 500-2250 mg a day (twice or three times per day)

Based on this trial design, predict the completion outcome and termination type (if applicable).